It is unknown whether a response to tolvaptan (TLV) is related to prognosis in patients with acute decompensated heart failure (ADHF). We selected 25 patients as responders by their urinary response to TLV and by reduction of loop diuretics from 37 consecutive ADHF patients treated with TLV. As a control group, we selected 25 patients from 100 consecutive ADHF patients who were not treated with TLV by propensity score matching for age, serum sodium level, serum creatinine level, plasma B-type natriuretic peptide (BNP) level, systolic blood pressure, heart rate, and dose of loop diuretics. The primary outcome was defined as a composite endpoint of mortality and/or hemodialysis. The amount of loop diuretics administered to responders was reduced by TLV from 68.8 ± 26.2 mg to 30.4 ± 18.6 mg of furosemide equivalents per day, whereas the loop diuretic dose administered to non-responders was increased. The event-free survival of the TLV responders during 20 months was significantly better than that of the control group (95.8% versus 68.4%, P = 0.0406). The TLV responders, plasma BNP level, and estimated glomerular filtration rate were significantly related to the events in the Cox proportional hazard analysis. Patients with ADHF who respond to TLV may have a better prognosis than propensity-matched patients not receiving TLV treatment. In TLV responders, it may be possible to improve the patient's prognosis if the dose of loop diuretics can be reduced with TLV therapy.
T olvaptan (TLV), a vasopressin V2 receptor antagonist, is an aquaretic agent often effective for the treatment of patients with refractory heart failure (HF), severe edema, or organ congestion unresponsive to high dosages of loop diuretics. However, TLV was not shown to improve the long-term prognosis of patients with acute decompensated HF (ADHF) in the EVEREST trial. 1) We have occasionally observed non-responders to TLV treatment, who have a poor incremental response in urine volume (UV) despite an administration of TLV for patients with ADHF, 2, 3) and the non-responders appear to have poor outcomes. ADHF patients who respond to TLV may have a better prognosis than non-responders. However, few prior studies have demonstrated an improved prognosis in these patients. It is often necessary to continue the long-term administration of large amounts of loop diuretics to prevent fluid retention in patients with HF with reduced ejection fraction (HFrEF).
4) The requirement for a large amount of loop diuretics has also been associated with poor prognosis. 5) Therefore, prognosis might be improved in ADHF patients who can tolerate a reduction in the dose of loop diuretics with TLV administration. We investigated mortality and morbidity, including hemodialysis and rehospitalization, in ADHF patients showing a response to TLV therapy as evidenced by a reduction in the amount of loop diuretics required and an increase in UV.
Methods

Study design and patients:
We studied the responses to TLV therapy and the outcomes in 37 ADHF patients who were administered TLV from September 2011 to September 2014 (T-group). We also investigated 100 patients with ADHF who received conventional HF treatment without TLV therapy during the same period (C-group). Data on basic characteristics and medication were obtained during hospitalization in the C-group or just before TLV administration in the T-group. Based on the patient's response to TLV therapy, patients were divided into two groups, responders and non-responders. A responder was defined as a patient who showed increased UV within 2 days of TLV administration and who tolerated a decreased dose of loop diuretics as a result. Twenty-five of 37 patients treated with TLV were classified as responders (TLV-R) and the others as non-responders (TLV-N). The beta blocker dose was calculated using carvedilol equivalent, which was defined as carvedilol 10 mg being equivalent to bisoprolol Nakamura, ET AL 2.5 mg. The loop diuretic dose was calculated using a furosemide equivalent, which was defined as furosemide 20 mg being equivalent to torasemide 4 mg or azosemide 30 mg. Urine volume was measured as urinary excretion per day before and after TLV administration, and the UV increase was calculated as the change in UV before and after TLV administration. TLV duration was calculated as the total administration period of TLV, and the TLV continuation rate was defined as the percentage of patients who continued to take TLV during the observational period. We performed propensity score matching to adjust patient background HF severity of patients in the C-group with those in the TLV-R group on the basis of age, serum sodium, creatinine, and plasma B-type natriuretic peptide (BNP) level, loop diuretic dose, systolic blood pressure, and heart rate with reference to the previous report, 6) and then selected 25 matched control patients (PS-C) from the 100 patients in the C-group. Clinical outcomes were analyzed using endpoints including hemodialysis and rehospitalization due to worsening HF in addition to all-cause mortality. The composite endpoint including the combination of all-cause mortality, hemodialysis, and rehospitalization due to HF was examined. Worsening renal function (WRF) was defined as an increase in serum creatinine level > 0.3 mg/dL from baseline during hospitalization.
To investigate factors related to all-cause mortality and hemodialysis, we examined the univariate and multivariate survival analysis using the log-rank test and Cox proportional hazard model. To analyze the prognostic impact of TLV treatment, we examined the rate of rehospitalization due to worsening HF, a requirement for hemodialysis, and all-cause mortality. Statistical Analysis: Data analyses were performed using R version 3.1.1 software. Categorical parameters are presented as frequencies and percentages unless otherwise described. For continuous variables, the mean ± SD (standard deviation) are given. Patient characteristics were compared using the unpaired t-test for continuous variables and the chi-squared test or Fisher's exact test for categorical variables, as appropriate. Propensity score nearest-neighbor matching was performed to adjust the HF severity of the control group to that of the TLV responder group on the basis of the seven factors previously described. Kaplan-Meier analysis was performed to assess all-cause mortality, the need for hemodialysis, and rehospitalization due to worsening HF in patients with/without TLV therapy, and each survival curve was analyzed with the log-rank test. A univariate analysis for survival and clinical factors was conducted using the log-rank test and Cox proportional hazards model. Multivariate analyses in the Cox proportional hazard models were constructed using three or six clinical prognostic factors, including the significant variables identified with univariate analyses in the TLV-R and PS-C groups. All statistical tests were twotailed, with P < 0.05 regarded as statistically significant.
Results
The clinical characteristics of patients in the T-group and C-group are shown in Table I . Patients in the T-group had significantly lower blood pressure and serum Na levels, and required a higher dose of loop diuretics than did those patients in the C-group (Table I) . Plasma BNP and Cr levels were not significantly different between the Tgroup and the C-group, although the serum Cr tended to be higher in the T-group.
Comparisons between TLV-R and TLV-N are shown in Table II . Serum Cr and BNP were higher in TLV-N than in TLV-R, but the differences were not significant. UVs were not increased after TLV administration in TLV-N, even though the TLV dose was significantly higher in TLV-N than in TLV-R (11.56 ± 4.367 mg versus 8.10 ± 3.85 mg, P = 0.0298). TLV administration reduced the amount of loop diuretics administered in TLV-R from 68.8 ± 26.2 mg to 30.4 ± 18.6 mg of furosemide equivalents per day, whereas the loop diuretic dose in TLV-N was increased ( Figure 1 ). Kaplan-Meier analysis showed that survival was significantly better in TLV-R than in TLV-N ( Figure 2 ).
Patient characteristics in TLV-R and PS-C were not significantly different, except for aldosterone antagonist usage and the loop diuretic dose, which were significantly higher in TLV-R despite having been matched by propensity scores (Table III) . The loop diuretics doses after treatment in TLV-R and in PS-C showed no difference, although the loop diuretic reduction in PS-C was small (from 31.6 ± 26.7 mg to 28.4 ± 26.1 mg). The large amount of aldosterone antagonist used in TLV-R was thought to be due to its use in combination with the high doses of loop diuretic. Although mortality, hemodialysis, rehospitalization, WRF (ΔCr > 0.3 mg/dL), and chronic kidney disease (CKD: eGFR (estimated glomerular filtration rate) < 60 mL/minute/1.73 m 2 ) tended to be lower in TLV-R than in PS-C, no statistically significant difference was observed.
TOLVAPTAN AND PROGNOSIS IN ACUTE HEART FAILURE
Kaplan-Meier analysis showed that the survival in TLV-R was better, but not significantly so, than in PS-C ( Figure 3A) . Event-free survival over 20 months (mean follow-up period, 290 days) was significantly better in TLV-R than in PS-C with regard to the composite endpoint of all-cause mortality and hemodialysis ( Figure 3B ; 95.8% versus 68.4%, P = 0.0406). The event-free survival curves, combined with mortality, hemodialysis, and rehospitalization, of TLV-R and PS-C were not significantly different ( Figure 3C ). Most events related to differences in the survival curves tended to occur within about one year.
Univariate survival analysis showed three significant variables related to the composite endpoint of mortality and hemodialysis: the response to TLV, plasma BNP levels, and eGFR (Table IV) . Multivariate models were constructed by clinical prognostic factors of three or six variables, including the factors found to be significant in the univariate analysis. The response to TLV, plasma BNP levels, and eGFR were significantly related to the composite outcome of all-cause mortality and hemodialysis in the Cox proportional hazards model (Table V) .
Discussion
In patients with ADHF, loop diuretics are the mainstay of therapy and effectively relieve symptoms. However, it is often necessary to continue the long-term administration of large amounts of loop diuretics to prevent fluid retention in patients with HFrEF, 4) and the use of large amounts of loop diuretics is a poor prognostic factor. 5) TLV is often effective for the treatment of patients with refractory HF, when an adequate response has not been obtained with loop diuretics. It is possible that adequate fluid control can be achieved with TLV administration alone, without the need for large amounts of loop diuretics, and TLV administration might prevent the induction of renal impairment by loop diuretics. 7, 8) Worsening renal function in heart failure is a prognostic factor: We have often observed impaired renal function occurring during hospitalization in patients with acute HF, so called WRF. 9, 10) A considerable number of patients admitted with ADHF have significant renal impairment, which influences treatment and outcomes. WRF occurs in Nakamura, ET AL ; log-rank test, P = 0.000274). B: Eventfree survival combined with mortality and hemodialysis comparing TLV-R with TLV-N (95.8% versus 0%, P = 0.0000812). C: Event-free survival combined with mortality, hemodialysis, and rehospitalization comparing TLV-R with PS-C (85.2% versus 0%, P = 0.000313).
20% to 30% of ADHF patients during hospitalization and soon after discharge. [11] [12] [13] It has been previously reported that the mortality rate is 2-3 times higher in patients that have WRF during hospitalization than in those without WRF. 12, 14) Of our 137 hospitalized ADHF patients, those in the TLV-treated group had elevated serum Cr levels, compared with those in the control group (Table I) . However, the frequency of WRF was lower (8%) in TLV-treated group, compared with 24% in the control group (Table  III) . Although this difference was not significant, TLV administration may not induce WRF in hospitalized patients with acute HF. Worsening renal function and large amounts of loop diuretics: Worsening renal function is caused by endogenous renal dysfunction, low cardiac output, and high venous pressure, and may occur during treatment with loop diuretics with subsequent sympathetic activation and the release of neurohumoral factors. 15) An increased diuretic dose and an increased frequency of inotrope use have been associated with an increase in the incidence of renal dysfunction. 16) In the treatment of acute HF, WRF was associated with high-dose loop diuretics and calcium antagonist use. 9) A higher maximum diuretic dosage in hospitalized HF patients is associated with a higher mortality rate. 17) High doses of loop diuretics are associated not only with WRF but also with poor prognosis and high mortality rate. In our ADHF patients, the mean doses of loop diuretics in the TLV and control groups were 61.4 mg and 13.4 mg of furosemide equivalents/day, respectively. In particular, TLV seemed to be administered to TOLVAPTAN WRF indicates worsening renal function; EF, ejection fraction; HFrEF, heart failure with reduced EF; ACE-I, angiotensin converting enzyme inhibitor; and AALD: aldosterone antagonist. † P < 0.1, logrank P = 0.0406. *P < 0.05. ; log-rank test, P = 0.115). B: Event-free survival combined with mortality and hemodialysis between TLV-R and PS-C (95.8% versus 68.4%, P = 0.0406). C: Event-free survival combined with mortality, hemodialysis, and rehospitalization comparing TLV-R with PS-C (85.2% versus 58.5%, P = 0.0999).
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those patients who were resistant to large amounts of loop diuretics, and this suggests that TLV administration did not increase WRF despite high loop diuretic dosages. TLV responders: TLV has been shown in several studies to ameliorate congestion through increased excretion of free water in the urine, 1) to stabilize hemodynamics, 18) and to correct hyponatremia. 19, 20) As such, the mechanisms of this drug are noteworthy, but it remains ineffective in certain patients with HF. 21) Imamura, et al. defined a responder as a patient with an increase in UV during the first 24 hours after the administration of TLV, and they suggested the use of new criteria that include the urine osmolality before and after the administration of TLV as a reliable predictor of a response to TLV. 2, 3) They also suggested the urine aquaporin-2 to plasma arginine vasopressin ratio as a novel predictor of the response to TLV in patients with decompensated HF.
6) The response predicted by this ratio may be accurate, but it is difficult to use in daily practice because urine aquaporin levels are not easily measured in a routine laboratory examination. Our definition of a response to TLV is based on simple clinical findings, though it is less accurate than the urine aquaporin-2 to plasma arginine vasopressin ratio. However, not only an increased UV but also a reduction in the loop diuretic dose after TLV administration (Table II, Figure 1) seems to be an important indicator of a TLV response, since high doses of loop diuretics may contribute to poor prognosis. TLV therapy reduced the use of loop diuretics: Matsue et al. reported WRF in 44 patients treated with TLV plus conventional therapy and in 70 patients treated only conventional therapy alone in ADHF. The incidence of WRF was significantly lower in the TLV-treated group than in the conventional therapy group. 7) However, they did not demonstrate that the dose of loop diuretics could be reduced by the administration of TLV, since the furosemide Nakamura, ET AL dose in the TLV-treated group was not different from that of the conventional therapy group. They also reported an add-on effect of TLV in patients with ADHF and renal dysfunction. 8) The TLV group showed more diuresis than the conventional group (6464.4 versus 4999.2 mL, P < 0.001) despite significantly lower loop diuretic doses (80 mg versus 120 mg, P < 0.001). However, the rate of WRF was not different between TLV and conventional groups (24.1% versus 27.8%, respectively; P = 0.642). Although the dose of loop diuretics was reduced, the rate of WRF could not be reduced in the study.
Shirakabe, et al. reported that TLV administration resulted in significantly greater UV when combined with low-dose furosemide than did conventional treatment in ADHF patients. In addition to the lower required dose of furosemide, TLV therapy also improved patient prognosis. 22) Hanatani, et al. also reported that the administration of TLV with lower doses of loop diuretics was clinically effective in improving congestion and renal dysfunction in patients with both congestive HF and renal dysfunction. 23) Overall, TLV appears to reduce the required dose of loop diuretics in patients with refractory HF.
In our analysis, although the total dose of loop diuretics was significantly higher in the TLV group, the incidence of WRF was not increased in the TLV-treated group. In the TLV treatment group, TLV responders were significantly better than non-responders for survival and each combined outcome of mortality, hemodialysis, and rehospitalization ( Figure 2A, B, C) . Furthermore, the composite endpoint of all-cause mortality and hemodialysis was significantly better in the TLV responder group than in the propensity-matched non-TLV-treated group ( Figure  3B ). Although there was no significant difference in mortality between the treatment groups, the survival curve of the TLV-treated group tended to be better than that of the control group ( Figure 3A) . It is possible to improve the prognosis in selected ADHF patients who respond to TLV administration with a reduction in the dose of loop diuretics. Furthermore, prognosis was associated with TLV response, plasma BNP levels, and eGFR, as shown by Cox proportional hazards model. ADHF patients that demonstrated an increased UV and a reduced loop diuretic dose with TLV therapy had an improved prognosis with regard to the composite end point, compared with patients not treated with TLV. However, there is no difference in loop diuretic dose between TLV-R and PS-C after TLV treatment, so reasons other than reducing loop diuresis in TLV treatment, such as an effect on the renin-angiotensin system, may also improve prognosis.
24)
Study limitations: First, this study was a retrospective analysis conducted in a single center and included a limited number of patients. In this study, we considered the addition of TLV therapy for patients who failed to respond to conventional therapy. Patients receiving TLV were generally more severely ill and more likely to have a poor outcome than patients not receiving TLV. A multicenter prospective study of a large number of patients should be conducted on responders to TLV.
Second, we used the propensity score matching method to compare patients treated with TLV with those not treated with TLV. Although propensity score matching was performed to select background-matched patients as a control group, the dose of loop diuretics in the TLV group, even after matching, was significantly higher than that seen in the control group. Patients undergoing TLV therapy received a much higher dose of loop diuretics than those who were not treated with TLV, so complete matched controls in the dose of loop diuretics could not be selected. However, the use of large amount loop diuretics in patients before TLV therapy may suggest that patients with TLV are at higher risk in HF than matched control patients.
Third, the dose of TLV was determined by several physicians considering the stability of patient hemodynamics and the degree of congestion, although the dose of TLV was not related to the response to TLV in this study.
Fourth, the present study had a patient selection bias because the decision to administer TLV was determined by physicians. Patients in the TLV-treated group received a relatively higher dose of diuretics than patients not receiving TLV therapy, probably because TLV was preferentially administered to those patients who were refractory to conventional diuretic therapy.
Conclusion
ADHF patients that responded to TLV therapy had good event-free survival reflected in a composite endpoint including hemodialysis and mortality, compared with similarly affected ADHF patients who did not receive TLV therapy. In TLV responders, it may be possible to improve the patient's prognosis if the dose of loop diuretics can be reduced with TLV therapy.
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